ICCM Stock Overview
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
IceCure Medical Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.19 |
| 52 Week High | US$1.57 |
| 52 Week Low | US$0.52 |
| Beta | 2.97 |
| 1 Month Change | 0.85% |
| 3 Month Change | -11.19% |
| 1 Year Change | -7.03% |
| 3 Year Change | -0.83% |
| 5 Year Change | n/a |
| Change since IPO | 1,008.01% |
Recent News & Updates
Recent updates
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate
Nov 29
Is IceCure Medical (NASDAQ:ICCM) In A Good Position To Deliver On Growth Plans?
Aug 08IceCure gains 19% on seeking FDA nod for cancer treatment
Oct 19IceCure files application for approval of ProSense in Canada for tumors
Jul 25IceCure Medical: Advancing Cryotherapy For Cancer Treatment
Jan 25Shareholder Returns
| ICCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.3% | 1.6% | 1.0% |
| 1Y | -7.0% | -1.4% | 21.9% |
Return vs Industry: ICCM underperformed the US Medical Equipment industry which returned -0.5% over the past year.
Return vs Market: ICCM underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| ICCM volatility | |
|---|---|
| ICCM Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ICCM has not had significant price volatility in the past 3 months.
Volatility Over Time: ICCM's weekly volatility has decreased from 18% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 74 | Eyal Shamir | icecure-medical.com |
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
IceCure Medical Ltd Fundamentals Summary
| ICCM fundamental statistics | |
|---|---|
| Market cap | US$54.42m |
| Earnings (TTM) | -US$14.65m |
| Revenue (TTM) | US$3.23m |
16.9x
P/S Ratio-3.7x
P/E RatioIs ICCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICCM income statement (TTM) | |
|---|---|
| Revenue | US$3.23m |
| Cost of Revenue | US$1.93m |
| Gross Profit | US$1.30m |
| Other Expenses | US$15.95m |
| Earnings | -US$14.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.32 |
| Gross Margin | 40.26% |
| Net Profit Margin | -453.76% |
| Debt/Equity Ratio | 0% |
How did ICCM perform over the long term?
See historical performance and comparison